Champions Oncology, Inc. (CSBR): Price and Financial Metrics


Champions Oncology, Inc. (CSBR): $10.45

-0.05 (-0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CSBR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 494

in industry

CSBR POWR Grades


  • CSBR scores best on the Sentiment dimension, with a Sentiment rank ahead of 90.99% of US stocks.
  • CSBR's strongest trending metric is Stability; it's been moving up over the last 30 weeks.
  • CSBR ranks lowest in Momentum; there it ranks in the 37th percentile.

CSBR Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CSBR is 5.53 -- better than 93.41% of US stocks.
  • With a price/earnings ratio of 392.08, Champions Oncology Inc P/E ratio is greater than that of about 97.81% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of 152.79%, Champions Oncology Inc's debt growth rate surpasses 93.23% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Champions Oncology Inc are NARI, ENV, PENN, OMCL, and CPSH.
  • Visit CSBR's SEC page to see the company's official filings. To visit the company's web site, go to www.championsoncology.com.

CSBR Valuation Summary

  • In comparison to the median Healthcare stock, CSBR's EV/EBIT ratio is 575.28% lower, now standing at -126.9.
  • CSBR's price/sales ratio has moved NA NA over the prior 176 months.
  • CSBR's price/earnings ratio has moved down 34.5 over the prior 176 months.

Below are key valuation metrics over time for CSBR.

Stock Date P/S P/B P/E EV/EBIT
CSBR 2019-10-24 2.4 38.9 -67.6 -78.8
CSBR 2019-10-01 2.3 37.3 -64.7 -75.5
CSBR 2016-05-26 2.6 13.3 -2.6 -2.3
CSBR 2015-03-09 2.7 -14.4 -2.8 -2.8
CSBR 2013-11-18 7.5 -6.4 -9.6 -8.6
CSBR 2010-01-04 6.2 92.9 -7.4 -7.3

CSBR Growth Metrics

  • Its 2 year net income to common stockholders growth rate is now at -33.81%.
  • The 5 year revenue growth rate now stands at 195.71%.
  • Its year over year net cashflow from operations growth rate is now at 56.02%.
Over the past 30 months, CSBR's revenue has gone up $17,792,000.

The table below shows CSBR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 39.224 2.844 -1.231
2020-09-30 37.424 2.988 -1.564
2020-06-30 34.932 2.469 -1.258
2020-03-31 32.123 2.905 -1.975
2019-12-31 31.093 0.612 -0.18
2019-09-30 28.511 1.543 -0.956

CSBR Price Target

For more insight on analysts targets of CSBR, see our CSBR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.00 Average Broker Recommendation 1.5 (Moderate Buy)

CSBR Stock Price Chart Interactive Chart >

Price chart for CSBR

CSBR Price/Volume Stats

Current price $10.45 52-week high $14.68
Prev. close $10.50 52-week low $7.05
Day low $10.40 Volume 8,300
Day high $10.67 Avg. volume 35,672
50-day MA $9.67 Dividend yield N/A
200-day MA $10.65 Market Cap 140.19M

Champions Oncology, Inc. (CSBR) Company Bio


Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.


CSBR Latest News Stream


Event/Time News Detail
Loading, please wait...

CSBR Latest Social Stream


Loading social stream, please wait...

View Full CSBR Social Stream

Latest CSBR News From Around the Web

Below are the latest news stories about Champions Oncology Inc that investors may wish to consider to help them evaluate CSBR as an investment opportunity.

Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development

HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space.

Yahoo | July 26, 2021

Champions Oncology Reports Quarterly Revenue of $10.6 Million

Record Annual Revenue of $41 MillionHACKENSACK, NJ / ACCESSWIRE / July 22, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in drug discovery and development, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2021.

Yahoo | July 22, 2021

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 22, 2021

HACKENSACK, NJ / ACCESSWIRE / July 14, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2021, on Thursday, July 22, 2021, before market open.

Yahoo | July 14, 2021

The Champions Oncology (NASDAQ:CSBR) Share Price Is Up 335% And Shareholders Are Delighted

While Champions Oncology, Inc. ( NASDAQ:CSBR ) shareholders are probably generally happy, the stock hasn't had...

Yahoo | July 8, 2021

BGI Americas partners with Champions Oncology to offer mass spectrometry-based proteomics and multiomics data analysis solutions

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- BGI Americas Corporation , a leading provider of genomics and proteomics services in the Americas as part of BGI Genomics Co. Ltd. (300676:Shenzhen), today announced a collaborative agreement with Champions Oncology (NASDAQ:CSBR), a leading global oncology data-driven solutions provider, to offer their respective customers end-to-end proteomics and multiomics solutions for oncology biomarker discovery and validation.

Intrado Digital Media | June 15, 2021

Read More 'CSBR' Stories Here

CSBR Price Returns

1-mo 10.93%
3-mo -0.67%
6-mo -8.97%
1-year 19.57%
3-year 32.28%
5-year 425.13%
YTD -3.15%
2020 29.53%
2019 6.66%
2018 101.29%
2017 53.36%
2016 -29.13%

Continue Researching CSBR

Want to see what other sources are saying about Champions Oncology Inc's financials and stock price? Try the links below:

Champions Oncology Inc (CSBR) Stock Price | Nasdaq
Champions Oncology Inc (CSBR) Stock Quote, History and News - Yahoo Finance
Champions Oncology Inc (CSBR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8489 seconds.